The current COVID-19 restrictions are posing significant challenges for research, particularly with many of us trying to balance working from home and physical distancing with increased clinical loads and family responsibilities. We appreciate this may limit your capacity to engage our services.
During this difficult time, we remain committed to ensuring that all cancer clinical trials group (CCTG) members and staff developing concepts, grant applications, and research projects with patient-reported outcomes (PROs) continue to receive full support from the Quality of Life Technical Service.
In response, we are replacing face-to-face workshops and presentations with online options. We’ll be uploading a series of online educational presentations that you can access over the coming weeks (the first is available now – please see details below).
Please also note that most of our resources are already online and accessible to all CCTG members and staff. The best way to contact us directly is via our online query form or by email.
Presentation Recordings
Short Education Presentations on PROs in clinical research.
A three-part series of short educational presentations covering the basic considerations for collecting Patient-Reported Outcomes (PROs) in clinical trial research.
Recommended for all new CCTG staff, and new investigators considering collecting Health-related Quality of Life and PROs in their studies.
Click on the links to access each presentation:
When prompted, enter the access code: QOL-TS
Presenter: Dr Claudia Rutherford
Senior Research Fellow
Deputy Director of the Sydney Quality of Life Office
School of Psychology, University of Sydney, NSW, Australia.
WEBINAR RECORDINGS
Interpreting Quality of Life and other Patient-Reported Outcomes
Quality of Life (QOL) and other patient-reported outcomes (PROs) provide information about the impact of disease and treatment on the patient.
QOL/PROs should be interpreted in the context of other trial outcomes to provide a comprehensive assessment of treatment benefits and harms. Statistical significance alone is not a sufficient means of interpreting changes in PRO scores in a way that is clinically meaningful.
In this webinar recording you will learn:
- How to interpret QOL PROs in a clinically meaningful way
- Current approaches to determining the smallest difference in a PRO that matters